Milestone Pharmaceuticals

MIST Lead: Approved ★ Read the deep dive → 8 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

CARDAMYST PSVT EU decision1H 2027CARDAMYST PSVT EU decision, 1H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

CARDAMYST

TACHYMIST · etripamil

Small Molecule Target: L-type calcium channel, AV node, calcium channel

Paroxysmal Supraventricular Tachycardia Approved nasal Everest Medicines NCT02296190

CARDAMYST

etripamil

Small Molecule Target: calcium channel

Atrial Fibrillation Phase 3 nasal NCT04467905

Biotech Distilled coverage (8)

2026-09-03 UPDATE: Milestone Pharmaceuticals (MIST) - The Pocket Hospital Clears China 🔒 Paid
2026-08-13 UPDATE: Milestone Pharmaceuticals (MIST) - The Scoreboard Just Tripled and Nobody Noticed 🔒 Paid
2026-05-14 UPDATE: Milestone Pharmaceuticals (MIST) - The First Scoreboard, and a Fresh $100M ATM 🔒 Paid
2026-04-27 UPDATE: Milestone Pharmaceuticals (MIST) - Express Scripts Says Yes, and the Stock Wakes Up 🔒 Paid
2026-03-21 UPDATE: Milestone Pharmaceuticals (MIST) - $200M War Chest and Slaying the Hypotension Bear 🔒 Paid
2026-02-14 Update: Milestone Pharmaceuticals (MIST) - Building the Foundation for Launch (and Deals) 🔒 Paid
2026-01-30 UPDATE: Milestone Pharmaceuticals (MIST) - CARDAMYST is on the Shelf. The Clock Starts Now.
2025-12-15 Milestone Pharmaceuticals (MIST): Scientific Due Diligence for CARDAMYST (etripamil) and Pipeline

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.